Emergent BioSolutions (EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread opioid emergency preparedness as opioid overdose death rates continue to decline nationwide for the first time in five years. These efforts include working with organizations to expand access to NARCAN Nasal Spray and educate the public on how to respond to an opioid overdose emergency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions, Rocketvax announce investment agreement
- Emergent BioSolutions Sells Baltimore Facility to Syngene
- Emergent BioSolutions to sell Baltimore-Bayview facility for $36.5M
- Emergent BioSolutions’ Earnings Call: Balancing Achievements and Challenges
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz